Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(8), P. 2705 - 2705
Published: April 15, 2025
Background: GLP1 receptor agonists (GLP1-RAs) have become a central component in the treatment of type 2 diabetes mellitus (T2DM) and are gaining prominence cardiovascular field. Semaglutide other GLP1-RA molecules possess cardioprotective properties. Cardiotoxicity, term used to refer disease caused by anticancer treatment, is collection common severe conditions. Its pharmacological prevention or mitigation clinical unmet need as options few limited some specific settings. GLP1-RAs promising profile given their activity on number pathophysiological targets signaling pathways including oxidative stress, autophagy, STAT3 activation. Interestingly, abnormalities GLP-1-modulated been linked cardiotoxicity. This scoping review aims map extent assess main characteristics research role and/or anticancer-related Methods: The selection process led inclusion thirteen studies chosen from reports retrieved through search string: (“semaglutide” OR “exenatide” “liraglutide” “dulaglutide” “tirzepatide” “GLP1 agonist” “GLP1RA” “GLP1-RA” “GLP1” “Glucagon-like Peptide-1 Agonists”) AND (“cardioncology” “cardiotoxicity” “chemotherapy” “anti-cancer treatment” therapy”). study complied with PRISMA guidelines reviews. Results: Two were conducted registries, eight animal models, two cell cultures, one was both models cultures. Evidence favor cardioprotection putative mechanisms emerged. Conclusions: GLP1-RAs’ effect cardiotoxicity quantity quality suffers poor standardization. However, most included documented rigorously defined demonstrated changes several pathophysiologically relevant pathways, NF-κB, IL-6, reactive oxygen species, caspase-3. Further warranted.
Language: Английский